Search results for "Elderly Patients"

showing 10 items of 40 documents

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Drug Prescription and Delirium in Older Inpatients: Results From the Nationwide Multicenter Italian Delirium Day 2015-2016

2019

Objective This study aimed to evaluate the association between polypharmacy and delirium, the association of specific drug categories with delirium, and the differences in drug-delirium association between medical and surgical units and according to dementia diagnosis. Methods Data were collected during 2 waves of Delirium Day, a multicenter delirium prevalence study including patients (aged 65 years or older) admitted to acute and long-term care wards in Italy (2015-2016); in this study, only patients enrolled in acute hospital wards were selected (n = 4,133). Delirium was assessed according to score on the 4 "A's" Test. Prescriptions were classified by main drug categories; polypharmacy w…

Malediagnosismedications0302 clinical medicinepreventionAged 80 and over; Delirium; Drug Prescriptions; Female; Hospital Departments; Humans; Male; Prevalence; Polypharmacy; Prescription Drugs80 and overPrevalenceMedicineLS4_4030212 general & internal medicineAcute hospitalmedia_commonAged 80 and overConfoundingelderly patients hip fracture hospitalized patients prediction rule risk factor dementia events medications prevention diagnosisrisk-factorrisk factorhip fracturePsychiatry and Mental HealthFemalemedicine.symptomeventsDrugmedicine.medical_specialtyPrescription Drugshospitalized-patientsmedia_common.quotation_subjectMEDLINEHospital DepartmentsSocio-culturaleelderly-patientselderly patientsbehavioral disciplines and activitiesDrug Prescriptions03 medical and health sciencesInternal medicinemental disordersDementiaHumansMedical prescriptionprediction ruleAgedPolypharmacybusiness.industryhospitalized patientsDeliriummedicine.diseasenervous system diseasesPolypharmacyDeliriumelderly-patients; hip fracture; hospitalized-patients; prediction rule; risk-factor; dementia; events; medications; prevention; diagnosisbusiness030217 neurology & neurosurgerydementia
researchProduct

Low Systolic Blood Pressure and Mortality in Elderly Patients After Acute Myocardial Infarction

2020

Background Optimal blood pressure in elderly patients after acute myocardial infarction is still a matter of debate. In a prospective observational study, we aimed to identify optimal systolic blood pressure during the 48 first hours after admission for acute myocardial infarction and its prognostic value for cardiovascular mortality. Methods and Results From the Observatoire des Infarctus de Côte d'Or survey, all consecutive patients aged >75 years admitted for an acute myocardial infarction in a coronary care unit from 2012 to 2015 and discharged alive were included (n=814). Exclusion criteria were in‐hospital death, cardiogenic shock, and end‐stage renal disease. Average systolic blo…

Malemedicine.medical_specialtyTime FactorsEpidemiologyMyocardial Infarctionacute myocardial infarction030204 cardiovascular system & hematologyelderly patientsRisk Assessment03 medical and health sciencesPatient Admission0302 clinical medicinecardiovascular mortalityInternal medicinemedicineCoronary Heart DiseaseHumansProspective Studies030212 general & internal medicineMyocardial infarctionNon-ST Elevated Myocardial InfarctionOriginal ResearchAgedCardiovascular mortalityAged 80 and overbusiness.industryAge Factorsblood pressurePrognosismedicine.diseaseBlood pressureHeart Disease Risk FactorsCardiologyST Elevation Myocardial InfarctionFemaleObservational studyCardiology and Cardiovascular MedicinebusinessJournal of the American Heart Association
researchProduct

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

2013

<b><i>Background:</i></b> Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderly patients because of its cardiotoxicity. <b><i>Patients and Methods:</i></b> Medical records of consecutive HER2-positive breast cancer patients aged ≥70 years old treated between 2005 and 2010 in the participating centers were retrospectively reviewed. All patients underwent multidimensional geriatric assessment (MGA). <b><i>Results:<…

OncologyCancer Researchmedicine.medical_specialtyAnthracyclineSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentPopulationAntineoplastic AgentsBreast NeoplasmsAntibodies Monoclonal HumanizedVentricular Function LeftBreast cancer; Elderly patients; Human epidermal growth factor receptor type 2; TrastuzumabBreast cancerBreast cancerTrastuzumabInternal medicinemedicineHumansAdverse effecteducationGeriatric AssessmentAgedRetrospective StudiesAged 80 and overChemotherapyCardiotoxicityeducation.field_of_studybusiness.industryRetrospective cohort studyGeneral MedicineTrastuzumabmedicine.diseaseHuman epidermal growth factor receptor type 2OncologyFemalebusinessElderly patientmedicine.drugOncology
researchProduct

Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.

2020

Nivolumab is an anti&ndash

OncologyMalemedicine.medical_specialtymedicine.medical_treatmentT cellelderly patients03 medical and health sciences0302 clinical medicineImmune systemmelanoma metastaticAntineoplastic Agents ImmunologicalInternal medicinemedicineHumans030212 general & internal medicineNeoplasm MetastasisMelanomaAgedbiologybusiness.industryMelanomaclinical benefitlactate dehydrogenaseImmunotherapymedicine.diseaseConfidence intervalelderly patientmedicine.anatomical_structureNivolumabTolerability030220 oncology & carcinogenesisbiology.proteinQuality of LifeFemaleOriginal ArticleImmunotherapyNivolumabAntibodybusinessCurrent oncology (Toronto, Ont.)
researchProduct

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

2013

A sequential approach including bortezomib induction, intermediate-dose melphalan, and autologous stem cell transplantation (ASCT), followed by lenalidomide consolidation-maintenance, has been evaluated. Efficacy and safety data have been analyzed on intention-to-treat and results updated. Newly diagnosed myeloma patients 65 to 75 years of age (n = 102) received 4 cycles of bortezomib-pegylated liposomal doxorubicin-dexamethasone, tandem melphalan (100 mg/m(2)) followed by ASCT (MEL100-ASCT), 4 cycles of lenalidomide-prednisone consolidation (LP), and lenalidomide maintenance (L) until disease progression. The complete response (CR) rate was 33% after MEL100-ASCT, 48% after LP and 53% after…

OncologyMelphalanMalemedicine.medical_specialtyImmunologyBortezomib-induction/Mel100-ASCT/lenalidomide consolidation-maintenance is effective in elderly patients with excellent performance status. Deaths related to AEs were higher in patients $70 years suggesting the need of a more careful patient selection.BiochemistryTransplantation AutologousDexamethasoneDisease-Free SurvivalDrug Administration SchedulePolyethylene GlycolsBortezomibAutologous stem-cell transplantationRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectLenalidomideMelphalanDexamethasoneMultiple myelomaLenalidomideAgedBortezomib-induction/Mel100-ASCT/lenalidomide consolidation-maintenance is effective in elderly patients with excellent performance status. Deaths related to AEs were higher in patients $70 yearsbusiness.industryBortezomibCell BiologyHematologyMiddle Agedmedicine.diseasesuggesting the need of a more careful patient selectionBoronic AcidsSurgeryThalidomideTransplantationTreatment OutcomeDoxorubicinPyrazinesDisease ProgressionFemalebusinessMultiple Myelomamedicine.drugStem Cell Transplantation
researchProduct

Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study

2017

Oncologymedicine.medical_specialty010405 organic chemistrybusiness.industrySettore MED/06 - Oncologia MedicabREast cancer In elDerly patiEntsHematology010402 general chemistrymedicine.disease01 natural sciencesMetastatic breast cancer0104 chemical sciencesBreast cancerOncologyInternal medicinemedicinebusinessNab-paclitaxel
researchProduct

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

2020

Background: TAS-102 is an oral monotherapy, combining trifluridine and tipiracil hydrochloride, indicated for the treatment of pretreated metastatic colorectal cancer (mCRC). The aim of this real-life study is to evaluate the efficacy and safety of TAS-102 in heavily pretreated elderly patients with mCRC whose disease has progressed with standard therapies. Methods: In this retrospective observational study, we enrolled 50 elderly patients >70 years of age (median age 78 years) with a diagnosis of mCRC who were previously treated or were not considered candidates for treatment with other available therapies. Patients aged >70 years with advanced colorectal cancer and with an ECOG perf…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentTrifluridineECOG Performance StatusDiseasechemotherapyelderly patientstrifluridine/tipiracilQuality of lifeInternal medicinemedicinelonsurfOriginal ResearchPharmacologyChemotherapybusiness.industrymetastatic colorectal cancertrifluridine/ tipiracillcsh:RM1-950Retrospective cohort studyGeneral Medicinemedicine.diseaselcsh:Therapeutics. PharmacologyTolerabilityquality of lifetas-102Molecular Medicinebusinessmedicine.drugDrugs in Context
researchProduct

PROGNOSTIC VALUE OF ESTIMATED GLOMERULAR FILTRATION RATE IN HOSPITALIZED ELDERLY PATIENTS

2013

A multicenter observational study, REPOSI (REgustri POliterapie Società Italiana di Medicina Interna), was conducted to assess the prognostic value of glomerular filtration rate (eGFR) on in-hospital mortality, hospital readmission and death within 3 months, in a sample of elderly patients (n=1,363) admitted to 66 internal medicine and geriatric wards. Bases on eGFR, calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, subjects at hostpital admission were classified into three groups: group 1 with normal eGFR (60 ml/min/1.73m2, reference group), group 2 with moderately reduced eGFR (30-59 ml/min/1.73 m2) and group 3 with severely reduced eGFR (<30 ml/m…

Settore MED/09 - Medicina InternaMulticenter study in-hospital elderly patients comorbidity polypharmacy eGFR
researchProduct

Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation.

2013

Settore MED/09 - Medicina Internacardio-embolic score; bleeding risk score; elderly patients; atrial fibrillation.cardio-embolic scorebleeding risk scoreelderly patientatrial fibrillation.
researchProduct